LifeStance Health Group (NASDAQ:LFST) Stock Price Down 3.4%

LifeStance Health Group, Inc. (NASDAQ:LFST – Get Rating) shares dropped 3.4% during mid-day trading on Friday . The stock traded as low as $7.77 and last traded at $7.85. Approximately 190,470 shares changed hands during trading, a decline of 66% from the average daily volume of 565,161 shares. The stock had previously closed at $8.13.

Analyst Upgrades and Downgrades

Separately, TD Cowen downgraded shares of LifeStance Health Group from an “outperform” rating to a “market perform” rating and boosted their price target for the company from $8.00 to $9.00 in a report on Monday, May 15th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, LifeStance Health Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.04.

LifeStance Health Group Trading Down 3.9 %

The firm has a fifty day moving average of $7.79 and a 200-day moving average of $6.12. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.15.

LifeStance Health Group (NASDAQ:LFST – Get Rating) last released its earnings results on Wednesday, May 10th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. LifeStance Health Group had a negative return on equity of 12.32% and a negative net margin of 20.63%. The firm had revenue of $252.59 million for the quarter, compared to analyst estimates of $246.04 million. As a group, equities analysts predict that LifeStance Health Group, Inc. will post -0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at LifeStance Health Group

In other news, insider Kevin Michael Mullins sold 97,266 shares of the firm’s stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $7.43, for a total transaction of $722,686.38. Following the sale, the insider now owns 5,512,581 shares of the company’s stock, valued at $40,958,476.83. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 264,066 shares of company stock valued at $1,744,368. 8.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its stake in LifeStance Health Group by 25.6% in the first quarter. JPMorgan Chase & Co. now owns 109,813 shares of the company’s stock valued at $816,000 after purchasing an additional 22,367 shares in the last quarter. Cim Investment Management Inc. bought a new position in shares of LifeStance Health Group during the 1st quarter worth approximately $233,000. Susquehanna International Group LLP bought a new position in shares of LifeStance Health Group during the 1st quarter worth approximately $244,000. Jane Street Group LLC bought a new position in shares of LifeStance Health Group during the 1st quarter worth approximately $188,000. Finally, Squarepoint Ops LLC boosted its stake in shares of LifeStance Health Group by 243.4% during the 1st quarter. Squarepoint Ops LLC now owns 43,032 shares of the company’s stock worth $320,000 after acquiring an additional 30,501 shares during the period. 76.49% of the stock is currently owned by institutional investors.

LifeStance Health Group Company Profile

(Get Rating)

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.